
PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device
Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants SALT LAKE CITY, UT, UNITED STATES, April 18, 2025 /EINPresswire.com/ -- PhotoPharmics, a leader in specialized light therapy for neurodegenerative diseases …